参考文献/References:
[1]Lehrer S,Rheinstein PH.Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer[J].Am J Clin Oncol,2020,43(10):685-689.[2]Wang J,Jia Y,Zhao S,et al.BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer[J].Oncogene,2017,36(45):6235-6243.[3]邢月,罗丹,杨承纲.膀胱尿路上皮癌中IDO和Bin1的表达及其临床意义[J].临床与实验病理学杂志,2018,34(10):1149-1152.[4]Ahmadzada T,Lee K,Clarke C,et al.High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes[J].Lung Cancer,2019,130(4):35-41.[5]Dong X,Zhang L,Meng Q,et al.Association Between Interleukin-1A,Interleukin-1B,and Bridging integrator 1 Polymorphisms and Alzheimer’s Disease:a standard and Cumulative Meta-analysis[J].Mol Neurobiol,2017,54(1):736-747.[6]王成钢,蒋志丽,李艳芳,等.桥接整合因子1在心源性哮喘与肺源性哮喘鉴别诊断中的意义[J].疑难病杂志,2020,19(5):467-471.[7]Hong TT,Yang H,Zhang SS,et al.Cardiac BIN1 folds T-tubule membrane,controlling ion flux and limiting arrhythmia[J].Nat Med,2014,20(6):624-632.[8]Pinali C,Malik N,Davenport JB,et al.Post-Myocardial Infarction T-tubules Form Enlarged Branched Structures With Dysregulation of Junctophilin-2 and Bridging Integrator 1 (BIN-1)[J].J Am Heart Assoc,2017,6(5):e004834.[9]Gambardella J,Wang XJ,Ferrara J,et al.Cardiac BIN1 Replacement Therapy Ameliorates Inotropy and Lusitropy in Heart Failure by Regulating Calcium Handling[J].JACC Basic Transl Sci,2020,5(6):579-581.[10]Romer SH,Metzger S,Peraza K,et al.A mouse model of Huntington’s disease shows altered ultrastructure of transverse tubules in skeletal muscle fibers[J].J Gen Physiol,2021,153(4):e202012637.[11]赵燕.先天性肌病临床、病理及分子生物学研究[D].石家庄:河北医科大学,2016.[12]Blumenau S,Foddis M,Müller S,et al.Investigating APOE,APP-Aβ metabolism genes and Alzheimer’s disease GWAS hits in brain small vessel ischemic disease[J].Sci Rep,2020,10(1):7103.[13]李杰,刘天旭,吕微,等.miR-28-3p通过抑制BIN1表达促进三阴性乳腺癌MDA-MB-468细胞的恶性生物学行为[J].中国肿瘤生物治疗杂志,2020,27(1):55-61.[14]Falcone S,Roman W,Hnia K,et al.N-WASP is required for Amphiphysin-2/BIN1-dependent nuclear positioning and triad organization in skeletal muscle and is involved in the pathophysiology of centronuclear myopathy[J].EMBO Mol Med,2014,6(11):1455-1475.[15]Ge Y,Schuster MB,Pundhir S,et al.The splicing factor RBM25 controls MYC activity in acute myeloid leukemia[J].Nat Commun,2019,10(1):172.[16]Wang X,Wang J,Jia Y,et al.Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition[J].Oncotarget,2017,8(12):19661-19673.[17]Pyndiah S,Tanida S,Ahmed KM,et al.c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1:a mechanism by which cancer cells acquire cisplatin resistance[J].Sci Signal,2011,4(166):ra19.[18]Sannerud R,Annaert W.Bin1 and CD2AP polarize Aβ generation in neurons[J].EMBO Rep,2017,18(1):5-7.[19]Xu B,Fu Y,Liu Y,et al.The ESCRT-III pathway facilitates cardiomyocyte release of cBIN1-containing microparticles[J].PLoS Biol,2017,15(8):e2002354.[20]Seidel T,Fiegle DJ,Baur TJ,et al.Glucocorticoids preserve the t-tubular system in ventricular cardiomyocytes by upregulation of autophagic flux[J].Basic Res Cardiol,2019,114(6):47.[21]Fu Y,Shaw SA,Naami R,et al.Isoproterenol Promotes Rapid Ryanodine Receptor Movement to Bridging Integrator 1 (BIN1)-Organized Dyads[J].Circulation,2016,133(4):388-397.[22]Hong TT,Smyth JW,Chu KY,et al.BIN1 is reduced and Cav1.2 trafficking is impaired in human failing cardiomyocytes[J].Heart Rhythm,2012,9(5):812-820.[23]Laury-Kleintop LD,Mulgrew JR,Heletz I,et al.Cardiac-specific disruption of Bin1 in mice enables a model of stress- and age-associated dilated cardiomyopathy[J].J Cell Biochem,2015,116(11):2541-2551.[24]Lawless M,Caldwell JL,Radcliffe EJ,et al.Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure[J].Sci Rep,2019,9(1):6801.[25]Muller AJ,Baker JF,DuHadaway JB,et al.Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation[J].Mol Cell Biol,2003,23(12):4295-4306.[26]Hong TT,Cogswell R,James CA,et al.Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy[J].Heart Rhythm,2012,9(6):961-967.[27]邹卓璇,邱英茹,陈浩,等.伊伐布雷定对慢性心力衰竭患者血浆桥接整合因子1含量的影响[J].现代生物医学进展,2019,19(15):2915-2919.[28]Nikolova AP,Hitzeman TC,Baum R,et al.Association of a Novel Diagnostic Biomarker,the Plasma Cardiac Bridging Integrator 1 Score,With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization[J].JAMA Cardiol,2018,3(12):1206-1210.[29]Li J,Agvanian S,Zhou K,et al.Exogenous Cardiac Bridging Integrator 1 Benefits Mouse Hearts With Pre-existing Pressure Overload-Induced Heart Failure[J].Front Physiol,2020(11):708.[30]安仕敏.甲状腺激素改善心力衰竭后心肌重塑的机制以及泛素特异性蛋白酶18对脂肪代谢、胰岛素抵抗和炎症的调控机制[D].北京:中国医学科学院北京协和医学院,2019.[31]Jiang M,Zhang M,Howren M,et al.JPH-2 interacts with Cai-handling proteins and ion channels in dyads:Contribution to premature ventricular contraction-induced cardiomyopathy[J].Heart Rhythm,2016,13(3):743-752.[32]Bryant SM,Kong CHT,Watson JJ,et al.Caveolin 3-dependent loss of t-tubular ICa during hypertrophy and heart failure in mice[J].Exp Physiol,2018,103(5):652-665.[33]An S,Gilani N,Huang Y,et al.Adverse transverse-tubule remodeling in a rat model of heart failure is attenuated with low-dose triiodothyronine treatment[J].Mol Med,2019,25(1):53.[34]Niermann C,Gorressen S,Klier M,et al.Oligophrenin1 protects mice against myocardial ischemia and reperfusion injury by modulating inflammation and myocardial apoptosis[J].Cell Signal,2016,28(8):967-978.
相似文献/References:
[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]程 林.重组人脑利钠肽用于重症急性心肌炎伴
心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,31(01):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[3]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,31(01):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[4]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(01):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[5]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,31(01):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[6]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Medical Information,2018,31(01):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[7]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,31(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Medical Information,2018,31(01):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
[8]李 宁,胡硕强.心脏再同步治疗心力衰竭的文献计量分析[J].医学信息,2018,31(19):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
LI Ning,HU Shou-qiang.Bibliometric Analysis of Cardiac Resynchronization in the Treatment of Heart Failure[J].Medical Information,2018,31(01):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
[9]颜 琼,王 静,胡 聪.慢性心力衰竭患者半年内重返住院的调查分析与对策[J].医学信息,2018,31(20):173.[doi:10.3969/j.issn.1006-1959.2018.20.055]
YAN Qiong,WANG Jing,HU Cong.Investigation and Countermeasures of Patients with Chronic Heart Failure Returning to Hospital within Half a Year[J].Medical Information,2018,31(01):173.[doi:10.3969/j.issn.1006-1959.2018.20.055]
[10]杨锦龙,刘 欢.甲状腺激素测定在高血压心力衰竭患者中的临床意义[J].医学信息,2018,31(22):96.[doi:10.3969/j.issn.1006-1959.2018.22.026]
YANG Jin-long,LIU Huanc.Clinical Signifcance of Changes of Serum Thyroid Hormone Levels in Hypertensive Patients with Chronic Heart Failure[J].Medical Information,2018,31(01):96.[doi:10.3969/j.issn.1006-1959.2018.22.026]